OUR R&D POLICY
Core Philosophy: Rising on an Unshakable Foundation
The absolute bioelectrical restoration we have achieved in four fatal infection models with completely different etiologies and in four different mammalian species is not a final destination reached by our R&D vision, but an unshakable foundation upon which we rise. This foundation is the experimental and clinical validation of the proposition that the bioelectrical code is a universal law. We have discovered this law; now we are expanding its boundaries.
Vision: Expanding the Boundaries of the Law
We aim to expand the boundaries of thermodynamics and biological time to the maximum level with the power of our technology. We have turned our R&D course, from the perspective of unmet medical needs, towards three main pathology classes united on the ground of bioelectrical collapse:
Ischemic tissues: The expansion of the tissue salvage window by bioelectrical restoration in myocardial infarction, cerebral ischemia, and peripheral artery diseases.
Chronic inflammatory processes: The bioelectrical reprogramming of low-grade chronic inflammation, ranging from autoimmune pathologies to metabolic syndrome.
Neurodegenerative pathologies: The activation of epigenetic repair programs in diseases characterized by the loss of bioelectrical integrity of neural networks, such as spinal cord paralysis, Alzheimer's, and Parkinson's.
Strategic Principle
Ontological Certainty If you succeed in coding the master software of life with biomimetic perfection, the question "I wonder if it will work in this disease too?" ontologically loses its meaning. Every pathology experiencing bioelectrical collapse is within the natural effect spectrum of this universal law and the Dr Biolyse® R&D vision. This is not an empirical hope, but a logical necessity arising from a validated law.
Our R&D Principles
Law-based research: We focus not on a specific disease, but on the ground of bioelectrical collapse where all diseases converge. Our signal does not change; its effect spectrum expands. Prospective validation: Every new indication is prospectively tested with predefined biomarkers and the Homeostasis Index. We predict, apply, and validate. Expanding the biological time window: We aim to halt the destruction kinetics leaping from linear to exponential through the timing of modulation, and to maximize the regenerative window.
Progressing with the awareness of limitations: We know that restoration is not possible in cases where the stem cell pool is depleted, total organ necrosis has occurred, or the biological time window is closed; we direct our R&D to expand these boundaries. Independent and methodologically pure research: All our R&D processes are conducted within the framework of ISO 14155, MDR, and FDA guidelines, with third-party independent researchers and under pharmacological isolation.
Conclusion
The Dr Biolyse® R&D policy is the realization of a logical necessity arising from the universality of the bioelectrical code, executed with scientific discipline. We are imitating a law. A law operates in every situation that falls within its scope. The aim of our R&D is to measure, map, and expand the boundaries of the pathological area covered by this law, step by step.